Compare Crocs, Inc. (CROX) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Stryker Corporation — how do they compare? Crocs, Inc. trades at $115.54 (market cap $5.60B), while Stryker Corporation trades at $278.55 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 19× Crocs, Inc.'s market cap, and Stryker Corporation pays a 1.27% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Stryker Corporation for 20 Days on average.
| CROX | SYK | |
|---|---|---|
Market Cap | $5.60B | $106.24B |
Volume | 1,026,773 | 2,982,001 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $388.35 |
52-Week Low | $73.39 | $269.75 |
Typical Hold Time | 96 Days | 20 Days |
Enterprise Value | $7.12B | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $115.20, down 4.18% amid bearish technical signals, though recent earnings beats and a 51% analyst buy rating suggest underlying strength. The stock shows attractive valuation with a P/E of 10.37 and strong profitability metrics including 57.47% gross margin and 42.3% ROE. Management is focusing on product innovation and HEYDUDE brand reset to drive growth.
Despite near-term price pressure, CROX offers value with consensus price target of $136.78 (19% upside). Risks include recent net income decline to -$81M and competitive pressures in footwear. The company's cash flow generation and brand positioning support long-term recovery potential.
Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.
Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
